Neurodegenerative Diseases News and Research

RSS

Human-worm connection research provides insight into brain development, diseases

"Man is but a worm" was the title of a famous caricature of Darwin's ideas in Victorian England. Now, 120 years later, a molecular analysis of mysterious marine creatures unexpectedly reveals our cousins as worms, indeed.

10 Feb 2011

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

CeNeRx BioPharma, Inc., a clinical-stage company developing and commercializing innovative treatments for diseases of the central nervous system (CNS), today announced FDA approval of its IND and reported the first clinical results in humans for CXB909, a novel agent that has demonstrated utility in preclinical models of neuroprotection and neurodegenerative disorders.

9 Feb 2011

Salk Institute receives $2.3 million CIRM grant for translational research on Parkinson's disease

The Salk Institute has been awarded a $2.3 million grant by the California Institute for Regenerative Medicine for translational research focusing on developing a novel stem cell based therapy for Parkinson's disease.

4 Feb 2011

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

A targeted delivery combination selectively crosses the tight barrier that protects the brain from the bloodstream to home in on and bind to brain tumors, a research team led by scientists from The University of Texas MD Anderson Cancer Center reported in the January issue of the Journal of Clinical Investigation.

2 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Research provides new clues for compulsive behavior, cognitive defects linked with LND

Research from the University of California, San Diego School of Medicine provides new clues for the compulsive behavior and cognitive defects associated with a rare childhood neurological disease called Lesch-Nyhan Disease.

29 Jan 2011

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

The Alzheimer's Drug Discovery Foundation announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to develop therapeutics targeted at clearing toxic proteins implicated in Alzheimer's disease.

28 Jan 2011

Cognition Therapeutics closes $2.5 million Series A1 financing

Cognition Therapeutics Inc., a drug discovery company developing novel, small molecule disease-modifying treatments for Alzheimer's, has closed on a $2.5 million Series A1 financing it will use to bring one or more of its compounds to Investigational New Drug (IND) candidate status. The round was led by Golden Seeds, one of the nation's largest angel investing groups, and was syndicated with Tech Coast Angels.

20 Jan 2011

Damaged alpha-synuclein proteins can spread in a 'prion-like' manner: Study

The study, published in the Journal of Clinical Investigation, reveals that damaged alpha-synuclein proteins can spread in a 'prion-like' manner, an infection model previously described for diseases such as BSE.

20 Jan 2011

Scientists discover fundamental mechanism behind toxic protein aggregation in neurodegenerative diseases

Protein aggregation underlies several neurodegenerative diseases such as Alzheimer's, Huntington's chorea or Parkinson's. Scientists at the Max Planck Institute of Biochemistry (MPIB) in Martinsried near Munich, Germany, now discovered a fundamental mechanism which explains how toxic protein aggregation occurs and why it leads to a widespread impairment of essential cellular functions.

20 Jan 2011

Study demonstrates role of alpha-synuclein cell-to-cell transfer in Parkinson's disease pathogenesis

The misfolding of abnormal proteins in brain cells is a key element in Parkinson's disease development. A recent study suggests that the sick proteins slowly move between cells, eventually triggering the destruction of the new host cell. The discovery could potentially lead to new therapeutic strategies for neurodegenerative diseases aimed at blocking the spread of protein misfolding throughout the brain.

19 Jan 2011

BSi and OMJPI enter development agreement for novel neurological and psychiatric disease therapeutics

The Johns Hopkins Brain Science Institute (BSi) announced today that it has entered into an agreement with Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI) to advance the development of novel therapeutics for neurological and psychiatric diseases.

19 Jan 2011

Researchers identify new biological pathway that contribute to glaucoma

In a study published today in the Proceedings of the National Academy of Sciences, a team of researchers from the Kennedy Krieger Institute and four collaborating institutions, identified a new and unexpected biological pathway that appears to contribute to the development of glaucoma and its resulting vision loss.

4 Jan 2011

AMPK activates autophagy by activating ATG1 enzyme

Researchers at the Salk Institute for Biological Studies have discovered how AMPK, a metabolic master switch that springs into gear when cells run low on energy, revs up a cellular recycling program to free up essential molecular building blocks in times of need.

24 Dec 2010

Biogen Idec acquires Neurimmune subsidiary

Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.

21 Dec 2010

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

With a grant of USD 475,000, the Michael J. Fox Foundation is funding preclinical development of a vaccine against Parkinson's disease by AFFiRiS AG. The vaccine, known as PD01, targets the protein alpha-synuclein and might offer for the first time a possibility for a treatment that can slow or stop the progression of Parkinson's disease.

17 Dec 2010

USAgainstAlzheimer's applauds House passage of National Alzheimer's Project Act

USAgainstAlzheimer's today applauded the passage by the House of Representatives of the National Alzheimer's Project Act and released statements from its Chairman and Founder George Vradenburg, its Scientific Advisory Board Chair and Nobel Laureate Stanley Prusiner and its ally in the Alzheimer's Movement, First Lady of California Maria Shriver.

16 Dec 2010

Neurodegenerative Diseases News and Research

Human-worm connection research provides insight into brain development, diseases

CeNeRx announces FDA approval of CXB909 IND for neuroprotection and neurodegenerative disorders

Salk Institute receives $2.3 million CIRM grant for translational research on Parkinson's disease

Targeted delivery combination crosses brain protecting barrier and homes in on tumors

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Research provides new clues for compulsive behavior, cognitive defects linked with LND

ALS Biopharma receives ADDF grant to develop therapeutics against Alzheimer's disease

Cognition Therapeutics closes $2.5 million Series A1 financing

Damaged alpha-synuclein proteins can spread in a 'prion-like' manner: Study

Scientists discover fundamental mechanism behind toxic protein aggregation in neurodegenerative diseases

Study demonstrates role of alpha-synuclein cell-to-cell transfer in Parkinson's disease pathogenesis

BSi and OMJPI enter development agreement for novel neurological and psychiatric disease therapeutics

Researchers identify new biological pathway that contribute to glaucoma

AMPK activates autophagy by activating ATG1 enzyme

Biogen Idec acquires Neurimmune subsidiary

AFFiRiS AG receives 475,000 MJFF grant for Parkinson vaccine development

USAgainstAlzheimer's applauds House passage of National Alzheimer's Project Act

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

Researchers examine expression of toxic mRNA in patients with Fragile X Tremor Ataxia Syndrome

Study finds expression of toxic RNA that leads to Fragile X Tremor Ataxia Syndrome modifiable

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News